Rem3dy Health, a Birmingham-based healthtech company specialising in personalised nutrition, has announced the successful closure of a €16 million funding round. The investment will support the company’s expansion into key international markets as it seeks to scale its operations globally.
Founded in 2019, Rem3dy Health has developed a platform designed to deliver personalised nutritional solutions to consumers. The funding round attracted a diverse investor syndicate, including Suntory, the major Japanese beverage manufacturer, Estrella Galicia, the Spanish beer producer, Apollo Hospitals, India’s largest healthcare network, UPSA, a pharmaceutical company, and Future Planet Capital Regional, a venture capital firm focused on impact investments.
Expansion Ambitions
The company’s leadership has emphasised the significance of this investment milestone. According to Melissa Snover, “Securing this funding marks a major milestone for us. Following a year of significant transformation and against one of the toughest fundraising environments in recent years, we are now in a strong position to scale globally,” Snover said.
The capital injection arrives as the healthtech sector continues to attract investor attention despite broader economic headwinds affecting venture funding. Rem3dy Health’s focus on personalised nutrition positions it within a growing segment of the health and wellness industry, where data-driven approaches to dietary intervention are gaining traction among both consumers and healthcare institutions.
The involvement of large corporate investors from the beverage and pharmaceutical sectors suggests confidence in the company’s business model and its potential to integrate into existing health and consumer product ecosystems. The backing from Apollo Hospitals also indicates possibilities for deployment within healthcare delivery networks, particularly in emerging markets.
Market Positioning
Rem3dy Health operates within the broader personalised nutrition space, which has experienced significant growth as consumers increasingly seek customised health solutions rather than one-size-fits-all approaches. The company’s ability to secure investment from such established players suggests it has developed proprietary technology or methodologies that differentiate it within this competitive landscape.
The €16 million round underscores the continued appetite among institutional investors for healthtech ventures, despite 2023 and early 2024 presenting notable challenges for European startups seeking capital. The multinational composition of Rem3dy Health’s investor base reflects how early-stage European companies increasingly attract international backing, particularly from companies seeking to integrate digital health capabilities into their existing portfolios.
As the UK’s healthtech ecosystem continues to mature, investments like this one contribute to Birmingham’s growing reputation as a centre for health-focused innovation outside of London. The city has increasingly attracted digital health ventures and corporate investment in recent years, complementing the broader UK life sciences sector’s expansion.